To address this, we have systematically targeted three key CMEs—DNMT, HDAC, and SETDB1—using single and combinatorial inhibitor treatments in three cancer types of endodermal origin, each with distinct functional status of p53. This evidence concerns the gene HDAC9 and cancer.